C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter C—Drugs: GeneralPart 201—LabelingSubpart D—Exemptions From Adequate Directions for Use

21 C.F.R. § 201.128 (2026)

Meaning of “intended uses”

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1981–2025 26citing cases
At a glance

Courts have cited this section in 26 opinions since 1981, 4 of them in the last five years.

The words intended uses or words of similar import in §§ 201.5, 201.115, 201.117, 201.119, 201.120, 201.122, and 1100.5 of this chapter refer to the objective intent of the persons legally responsible for the labeling of an article (or their representatives). The intent may be shown by such persons' expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article. This objective intent may, for example, be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives. Objective intent may be shown, for example, by circumstances in which the article is, with the knowledge of such persons or their representatives, offered or used for a purpose for which it is neither labeled nor advertised; provided, however, that a firm would not be regarded as intending an unapproved new use for an approved drug based solely on that firm's knowledge that such drug was being prescribed or used by health care providers for such use. The intended uses of an article may change after it has been introduced into interstate commerce by its manufacturer. If, for example, a packer, distributor, or seller intends an article for different uses than those intended by the person from whom he or she received the article, such packer, distributor, or seller is required to supply adequate labeling in accordance with the new intended uses.

[86 FR 41401, Aug. 2, 2021]
The 20 cases that cite 21 C.F.R. § 201.128 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENUnited States v. Caronia, 703 F.3d 149 (2d Cir. 2012).
cites § 201.128 6×cited by 77 cases
Where it cites § 201.128
“" 21 C.F.R. § 201.128 . The consequences for misbranding are criminal.”
The case’s holding
The First Amendment prohibits the government from criminalizing the truthful, non-misleading promotion of an FDA-approved drug for off-label use.
Later courts cite it for
“once fda-approved, prescription drugs can be prescribed by doctors for both fda-approved and -unapproved uses; the fda generally does not regulate how physicians use approved drugs.” · 4 citing courts
2
GREENUnited States ex rel. Polansky v. Pfizer, Inc., 822 F.3d 613 (2d Cir. 2016).
cites § 201.128 2×cited by 21 cases
Where it cites § 201.128
“5 ; see also 21 C.F.R. § 201.128 (definition of "intended uses").”
Later courts cite it for
“caronia left open the government's ability to prove misbranding on a theory that promotional speech provides evidence that a drug is intended for a use that is not included on the drug's fda- approved label.” · 2 citing courts
3
GREENCoyne Beahm, Inc. v. United States Food & Drug Admin., 966 F. Supp. 1374 (M.D.N.C. 1997).
cites § 201.128 3×cited by 15 cases
Where it cites § 201.128
“See 21 C.F.R. §§ 201.128 , 801.4 (defining “intended use” regarding drugs and devices, respectively).”
The case’s holding
Tobacco products fall within the statutory definitions of drugs and devices because they are intended to affect the structure or function of the body.
Later courts cite it for
“it is further ordered that the food and drug administration shall not implement any of the additional regulations set for implementation on august 28, 1997, pending further orders by the court.” · 4 citing courts
4
GREENUnited States v. Kasz Enter., Inc., 855 F. Supp. 534 (D.R.I. 1994).
cites § 201.128 3×cited by 14 cases
Later courts cite it for
“can be demonstrated by ... evidence that the vendor is aware that his product is being offered or used by others for a purpose for which it is neither labeled nor advertised.” · 2 citing courts
5
REDUnited States v. Caronia, 576 F. Supp. 2d 385 (E.D.N.Y. 2008).
cites § 201.128 2×cited by 8 cases
Vacated by United States v. Caronia (2012): the Court of Appeals for the Second Circuit's own opinion in this case.
Where it cites § 201.128
“” 21 C.F.R. § 201.128 ; see also Action on Smoking and Health v.”
6
GREENKnipe v. Smithkline Beecham, 583 F. Supp. 2d 602 (E.D. Pa. 2008).
cites § 201.128 1×cited by 21 cases
Where it cites § 201.128
“See 21 C.F.R. § 201.128 ("if a manufacturer knows, or has knowledge of facts that would give him notice, that a drug introduced into interstate commerce by him is to be used for conditions, purposes or uses other than the one for which he offers it, he is required to provide…”
The case’s holding
Where a true conflict exists under Pennsylvania choice of law analysis, the state where the drug was prescribed, ingested, and caused injury has the greater interest and its law governs.
Later courts cite it for
“the mere fact that defendant resides in pennsylvania and conducts some business there simply does not outweigh new jersey's dual interests of protecting its citizens and regulating business conduct occurring within its borders.” · 3 citing courts
7
GREENAventis Pharm., Inc. v. Barr Labs., Inc., 411 F. Supp. 2d 490 (D.N.J. 2006).
cites § 201.128 2×cited by 6 cases
Where it cites § 201.128
“Plaintiffs point to 21 C.F.R. § 201.128 , which, in conjunction with 21 C.”
8
GREENAllergan, Inc. v. Athena Cosmetics, Inc., 738 F.3d 1350 (Fed. Cir. 2013).
cites § 201.128 1×cited by 18 cases
Where it cites § 201.128
“” 21 C.F.R. § 201.128 . Objective intent “is determined by such persons’ expressions or may be shown by the circumstances surrounding the distribution of the article,” including “labeling claims, advertising matter, or oral or written statements by such persons or their…”
Later courts cite it for
“incorporates various provisions of the fdca, which does not itself allow a private right of action.” · 2 citing courts
9
GREENSpectrum Pharm., Inc v. Sylvia Burwell, 824 F.3d 1062 (D.C. Cir. 2016).
cites § 201.128 1×cited by 7 cases
Where it cites § 201.128
“” 21 C.F.R. § 201.128 . Under that regulation, intent “is determined by such persons’ expressions” or “may be shown by the circumstances surrounding the distribution” of the drugs.”
Later courts cite it for
“designed to treat a rare disease or condition that historically received little attention from pharmaceutical companies.” · 2 citing courts
10
GREENSmoking Everywhere, Inc. v. U.S. Food & Drug Admin., 680 F. Supp. 2d 62 (D.D.C. 2010).
cites § 201.128 1×cited by 16 cases
Where it cites § 201.128
“21 C.F.R. § 201.128 . Objective intent may be shown, for example, “by labeling claims, advertising matter, or oral or written statements” by the labeler.”
Later courts cite it for
“the party seeking a preliminary injunction need not prevail on each factor.” · 2 citing courts
11
GREENUnited States v. Regenerative Sciences, LLC, 741 F.3d 1314 (D.C. Cir. 2014).
cites § 201.128 1×cited by 15 cases
Where it cites § 201.128
“be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives”).”
Later courts cite it for
“would be unnecessary if the fdca did not otherwise regulate the distribution of drugs by licensed physicians.” · 1 citing court
12
GREENUnited States v. H. Ray Evers, M. D., 643 F.2d 1043 (5th Cir. 1981).
cites § 201.128 1×cited by 31 cases
Where it cites § 201.128
“” 21 C.F.R. § 201.128 . Since Dr. Evers clearly intended to use Calcium EDTA for the treatment of arteriosclerosis, these provisions would seem to require him to provide adequate directions in lay terms to his patients for the use of Calcium EDTA in the treatment of…”
The case’s holding
A physician who distributes prescription drugs only to their own patients does not hold those drugs for sale under the misbranding statute.
Later courts cite it for
“while the fdca was not intended to regulate the practice of medicine, it was obviously intended to control the availability of drugs for prescribing by physicians.” · 5 citing courts
13
GREENUnited States v. Travia, 180 F. Supp. 2d 115 (D.D.C. 2001).
cites § 201.128 2×cited by 3 cases
Where it cites § 201.128
“, 21 C.F.R. § 201.128 (“The words ‘intended uses’ .”
14
GREENUnited States v. Cole, 84 F. Supp. 3d 1159 (D. Or. 2015).
cites § 201.128 2×cited by 3 cases
Where it cites § 201.128
“” 21 C.F.R. § 201.128 . In general, express or implied claims that a product can be used to diagnose, cure, mitigate, treat, or prevent a disease are evidence of a vendor’s intent that the product be used for such purposes.”
cites § 201.128 2×cited by 5 cases
Where it cites § 201.128
“1969); 21 C.F.R. § 201.128 . This is true even if the products labelling states that it is not a drug.”
cites § 201.128 1×cited by 7 cases
Where it cites § 201.128
“” 21 C.F.R. § 201.128 . While this definition is surely broad enough to encompass the circumstance here, that fact is of no legal consequence because "no order or regulation issued by an administrative agency can confer on it any greater authority than it has under statute.”
17
GREENSigma-Tau Pharm., Inc. v. Schwetz, 288 F.3d 141 (4th Cir. 2002).
cites § 201.128 2×cited by 10 cases
Where it cites § 201.128
“In particular, Sigma-Tau contends that if the agency had properly applied its intended-use regulation, 21 C.F.R. § 201.128 (2001), it would have concluded that the generics at issue were intended for treatment of ESRD patients.”
Later courts cite it for
“directed at fda approved-use, not generic competitor intended-use” · 3 citing courts
18
GREENBaker v. Johnson & Johnson, 709 F. Supp. 2d 677 (S.D. Ill. 2010).
cites § 201.128 1×cited by 6 cases
Where it cites § 201.128
“Defendants contend that because the complaint contains a count alleging negligence per se on the basis of an alleged violation by Defendants of 21 C.F.R. § 201.128 , the negligence per se count constitutes a separate and independent claim arising under federal law within the…”
19
GREENUnited States v. Regenerative Sciences, LLC, 878 F. Supp. 2d 248 (D.D.C. 2012).
cites § 201.128 1×cited by 6 cases
Where it cites § 201.128
“1980) (internal quotation marks and citations omitted); see 21 C.F.R. § 201.128 (“The words intended uses or words of similar import in §§ 201.”
Later courts cite it for
“to constitute final agency action, two conditions must be met: (1) 'the action must mark the consummation of the agency's decisionmaking process' and (2) it 'must be one by which rights or obligations have been determined, or from which legal consequences will flow.” · 2 citing courts
20
GREENUnited States v. Lane Labs-USA, Inc., 324 F. Supp. 2d 547 (D.N.J. 2004).
cites § 201.128 1×cited by 5 cases
Where it cites § 201.128
“” 21 C.F.R. § 201.128 (emphasis added)(“The intent is determined by such persons’ expressions or may be shown by the circumstances surrounding the distribution of the article.”

Show all 26 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
198120032025

One bar per year. Tallest: 2 cases in 1997. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.D.C.42d Cir.2D.C. Cir.2M.D.N.C.2D.N.J.210th Cir.111th Cir.14th Cir.1

The 8 courts with the most citing cases, of 19 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Show all 26 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com